INGREZZA Drug Patent Profile

Which patents cover Ingrezza, and when can generic versions of Ingrezza launch?

Ingrezza is a drug marketed by Neurocrine and is included in two NDAs. There are twenty-two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-eight patent family members in thirty-seven countries.

The generic ingredient in INGREZZA is valbenazine tosylate. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ingrezza

A generic version of INGREZZA was approved as valbenazine tosylate by LUPIN on April 5^th, 2024.

Summary for INGREZZA

International Patents:	278
US Patents:	22
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	7
Patent Applications:	254
Drug Prices:	Drug price information for INGREZZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INGREZZA
What excipients (inactive ingredients) are in INGREZZA?	INGREZZA excipients list
DailyMed Link:	INGREZZA at DailyMed

See drug prices for INGREZZA

Recent Clinical Trials for INGREZZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stephen Ruedrich	Phase 4
Neurocrine Biosciences	Phase 4
Michael Bloch	Phase 2

See all INGREZZA clinical trials

Pharmacology for INGREZZA

Drug Class	Vesicular Monoamine Transporter 2 Inhibitor
Mechanism of Action	Vesicular Monoamine Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INGREZZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INGREZZA	Capsules	valbenazine tosylate	60 mg	209241	1	2022-02-14
INGREZZA	Capsules	valbenazine tosylate	40 mg and 80 mg	209241	4	2021-04-12

US Patents and Regulatory Information for INGREZZA

INGREZZA is protected by thirty-three US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes			Y	Y
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-003	Apr 23, 2021		RX	Yes	No
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-001	Apr 11, 2017	AB	RX	Yes	No			Y	Y
Neurocrine	INGREZZA SPRINKLE	valbenazine tosylate	CAPSULE;ORAL	218390-002	Apr 30, 2024		RX	Yes	No
Neurocrine	INGREZZA	valbenazine tosylate	CAPSULE;ORAL	209241-002	Oct 4, 2017	AB	RX	Yes	Yes			Y

International Patents for INGREZZA

When does loss-of-exclusivity occur for INGREZZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Morocco

Poland

Portugal

San Marino

Serbia

Slovenia

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INGREZZA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016343633
Brazil	112018008460
Canada	3002074
Chile	2018001089
China	108473489
China	115304596

Ingrezza (valbenazine) Market Dynamics and Financial Trajectory: Exclusivity, Competitive Pressure, Pricing, and Revenue Outlook

Last updated: July 21, 2026

Ingrezza (valbenazine) has established commercial scale for tardive dyskinesia, with revenue performance shaped by (1) remaining patent and regulatory exclusivity, (2) competitive branded and payer pressure, (3) uptake into schizophrenia-associated tardive dyskinesia subpopulations, and (4) formulary access versus generics/biosimilar-like substitutes. The financial trajectory is driven by calendar-year ramp after the initial launch and then by mid-course erosion and gross-to-net pressure as managed-care contracts tightened and competing therapies gained share.

---

What is Ingrezza (valbenazine) used for, and how do those indications drive demand?

Ingrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor used for:

• Tardive dyskinesia (TD) (adult patients)
• Often discussed in market materials alongside symptom burden in movement-disorder populations with high comorbidity loads (psychiatric and neurologic)

Why does TD demand behave differently from many neuropsychiatric drugs?

TD is a chronic, treatment-responsive condition with ongoing symptom recurrence risk. That supports “replace over time” demand rather than episodic demand, but it also increases the intensity of payer management because long-term coverage decisions affect lifetime value.

What patient segments most influence Ingrezza prescribing?

• Patients with persistent TD symptoms after antipsychotic exposure
• Patients where clinicians seek faster symptom control without switching antipsychotics for tolerability reasons
• Health plans that use step edits or restricted formularies for VMAT2 inhibitors

---

How have Ingrezza sales trended since launch, and what is the likely financial trajectory?

Ingrezza has been one of the more durable specialty launches in movement disorders, with sales growth tied to expanding prescriber comfort, payer access, and conversion from off-label or alternative symptomatic approaches.

Sales inflection points that typically matter for Ingrezza

• Post-launch formulary expansion: Managed care contracting is often the largest driver of mid-cycle demand acceleration after initial adoption.
• Guideline and access reinforcement: Coverage decisions often track guideline updates and real-world tolerability data.
• Competitive friction: Gross-to-net usually compresses before unit sales peak when payers tighten tiering and require higher rebates.

What does “financial trajectory” mean in Ingrezza’s context?

For specialty movement-disorder drugs, revenue often tracks:

• Net sales growth (unit growth, patients treated, adherence)
• Gross-to-net changes (rebates, copay programs, channel mix)
• Pricing resets driven by contract negotiations and competitive contracting pressure

A practical outcome is that net sales may show slower growth even if prescriptions continue to rise, because rebates adjust.

---

What patents protect Ingrezza, and when does exclusivity end?

Ingrezza’s competitive risk is largely a function of:

• Patent expiration for the drug substance and compositions
• Patent expiration for formulations, dosing regimens, and method-of-treatment claims
• Regulatory exclusivity and Orange Book protections (application-specific exclusivity periods and listed patents)

How to think about “when does exclusivity lose?”

For a brand with multiple listed Orange Book patents, market risk typically escalates when the earliest relevant claim set expires for either:

• The active ingredient (substance)
• The composition/formulation (including crystal forms, polymorphs, or specific excipients)
• Method-of-use (TD treatment paradigms)
• Manufacturing (process or intermediates)

---

What is the Orange Book status of Ingrezza, and what generic entry risks exist?

Orange Book status determines whether an ANDA filer can certify to a listed patent and which certification pathways are available.

What to look for in Orange Book listings

• Number of listed patents covering:
  • Drug substance
  • Drug product (formulation)
  • Method of use
  • Manufacturing/process
• The earliest “expiration” date among those patents
• Whether later-expiring patents create a de facto blocking position even after an earlier patent expires

Paragraph IV risk

If a generic applicant files a Paragraph IV certification against one or more listed patents, the market consequence is:

• Potential for entry-at-risk (if it is not enjoined)
• Triggering of stay/settlement leverage
• Deflection of payer contracting schedules if litigation is active

---

What patent litigation affects Ingrezza, and how does that change generic timing?

For branded neuro specialty drugs with meaningful revenue, litigation risk is typically concentrated around:

• Composition/formulation patents
• Method-of-use patents
• Drug substance polymorph/intermediate patents (if applicable)

Litigation outcome paths that matter commercially

• No injunction: generic launch can occur soon after the earliest break
• Injunction: delays entry and extends rebate-driven pricing power
• Settlement: creates a defined “carve-out” or entry date that payers may incorporate into contracting

---

Who are the main competitors to Ingrezza, and how does competition impact pricing and share?

Competition in tardive dyskinesia VMAT2 space and broader movement-disorder treatment choices can affect Ingrezza through:

• Formulary tiering (preferred vs non-preferred)
• Prior authorization tightening
• Step therapy requirements
• Copay card economics (where allowed)
• Rebate rebalancing based on competitor penetration

Competitive pressure mechanisms common in TD

• Payers move to preferred status for the least expensive covered option
• Plans push for outcomes-based approvals, limiting duration without documentation
• “Fail-first” policies can redirect new starts

---

How does Ingrezza compare with other VMAT2 inhibitors for tardive dyskinesia?

Within VMAT2 inhibitor competition, commercial dynamics depend on:

• Dosing convenience and adherence profiles
• Adverse event burden and discontinuation rates
• Evidence base and clinician familiarity
• Payer access differences driven by contract terms

What typically determines market share in VMAT2 competition?

• Formulary placement
• Specialty pharmacy reimbursement and patient out-of-pocket
• Prescriber switching behavior after early payer coverage issues

---

What formulation and manufacturing/IP barriers could slow generic or biosimilar-like entry?

Even after drug-substance patent timelines approach, entry can be delayed by:

• Composition/formulation patents (specific dosage form details)
• Manufacturing/process patents covering steps, intermediates, or purification
• Specific physicochemical characteristics tied to stability and bioavailability

What barriers matter most for oral specialty TD drugs?

• Stability requirements for consistent bioavailability
• Manufacturing scalability without crossing protected process steps
• Analytical methods that may be part of a claimed method or control strategy

---

How do FDA regulatory milestones shape market access for Ingrezza?

FDA-related dynamics affecting commercial trajectory include:

• Label scope (which can expand or limit reimbursement eligibility)
• Safety communications that influence prescribing patterns
• Postmarketing commitments affecting clinician confidence
• Generic application approvals if exclusivity barriers fall

What matters most for payer contracting?

• Duration and breadth of labeled use that aligns with plan coverage criteria
• Safety profile consistency with plan utilization management

---

What revenue exposure does Ingrezza face from exclusivity expiry and price erosion?

Revenue exposure typically concentrates on:

• The earliest date at which generic entry becomes legally possible
• The probability of successful Paragraph IV defenses or settlements
• The magnitude of payer price pressure once a therapeutic alternative becomes available

How market usually reacts to anticipated entry

• Payers may front-load rebates and tighten formulary restrictions ahead of loss of exclusivity
• Brands often increase contracting aggressiveness to protect net price
• Distribution and patient assistance may change to maintain net revenue per covered patient

---

What settlement agreements or licensing deals affect Ingrezza’s competitive position?

In major oral specialty drugs, licensing or settlement can:

• Convert uncertain litigation timing into a predictable entry schedule
• Include “no-launch” covenants or market carve-outs
• Define permissible launch geographies or launch product attributes

What to look for

• Named defendants and patent groups
• Settlement date and effective start of entry restrictions
• Scope exclusions (specific patents only, product strengths, formulation changes)

---

Key takeaways

• Ingrezza’s financial trajectory is driven by chronic TD treatment demand plus the managed-care mechanics that shape net sales through gross-to-net and formulary access.
• The principal competitive risk is legal and regulatory: Orange Book patent cliffs, Paragraph IV litigation outcomes, and any settlement-driven entry dates.
• Patent estate structure matters as much as substance expiration; composition and method-of-use patents often extend practical exclusivity.
• Commercial share changes are likely to occur first through payer contracting and prior authorization tightening, then through unit-level erosion once a lower-cost alternative is available.
• Revenue exposure spikes when the earliest legally actionable patent ends; the magnitude depends on likelihood of at-risk entry versus injunction and settlement terms.

---

FAQs

1) When do Ingrezza patents first expire, and which listed patents are usually the entry blockers?

2) What Paragraph IV filings are most relevant for Ingrezza, and what litigation stages determine launch timing?

3) How do gross-to-net and rebate changes typically evolve for Ingrezza once competitive contracting increases?

4) What payer restrictions (prior authorization, step edits, quantity limits) most affect Ingrezza new starts?

5) What generic entry scenarios are most realistic for Ingrezza by strength, formulation, and label carve-outs?

---

References

1. [No sources were provided in the prompt; references cannot be generated without cited material.]

DrugChatter Q&A for INGREZZA

Is there a generic drug for ingrezza?
Why ingrezza is not available in europe?
Ingrezza cap expiry dating period?
When will ingrezza patent expire?
Can ingrezza make hand tremors worse?